Vetr cut shares of Amgen Inc. (NASDAQ:AMGN) from a strong-buy rating to a buy rating in a report released on Tuesday morning. They currently have $185.76 target price on the medical research company’s stock.
AMGN has been the topic of a number of other research reports. Jefferies Group upped their target price on shares of Amgen from $187.00 to $198.00 and gave the company a buy rating in a research report on Thursday, July 28th. Zacks Investment Research raised shares of Amgen from a hold rating to a buy rating and set a $166.00 target price on the stock in a research report on Wednesday, June 29th. Citigroup Inc. decreased their target price on shares of Amgen from $175.00 to $172.00 and set a neutral rating on the stock in a research report on Wednesday, September 28th. Leerink Swann reaffirmed a hold rating on shares of Amgen in a research report on Sunday, June 26th. Finally, Argus reaffirmed a buy rating and issued a $195.00 target price (up previously from $185.00) on shares of Amgen in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Amgen currently has an average rating of Buy and a consensus target price of $184.94.
Amgen (NASDAQ:AMGN) opened at 167.50 on Tuesday. The stock has a 50 day moving average of $170.75 and a 200-day moving average of $161.82. Amgen has a 12 month low of $139.02 and a 12 month high of $176.85. The stock has a market cap of $125.35 billion, a P/E ratio of 17.14 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS. On average, equities analysts forecast that Amgen will post $11.35 EPS for the current fiscal year.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.20% of the company’s stock.
Large investors have recently modified their holdings of the company. Advisory Services Network LLC increased its stake in shares of Amgen by 11.2% in the third quarter. Advisory Services Network LLC now owns 10,793 shares of the medical research company’s stock valued at $1,800,000 after buying an additional 1,085 shares in the last quarter. Sadoff Investment Management LLC acquired a new stake in Amgen during the third quarter worth approximately $220,000. Catawba Capital Management VA increased its stake in Amgen by 31.8% in the third quarter. Catawba Capital Management VA now owns 5,320 shares of the medical research company’s stock worth $887,000 after buying an additional 1,285 shares during the period. Oliver Luxxe Assets LLC increased its stake in Amgen by 13.8% in the third quarter. Oliver Luxxe Assets LLC now owns 3,849 shares of the medical research company’s stock worth $642,000 after buying an additional 467 shares during the period. Finally, R.H. Dinel Investment Counsel Inc. increased its stake in Amgen by 1.7% in the third quarter. R.H. Dinel Investment Counsel Inc. now owns 22,400 shares of the medical research company’s stock worth $3,737,000 after buying an additional 375 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.